Loading…
BriaCell Therapeutics Corp. is projected to decline to $3.85 by 2027, a -2% move from its current price of $3.94. BCTX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $3.77 | $3.94 | $4.11 | -0.07% |
| Jul 13 | $3.70 | $3.93 | $4.18 | -0.14% |
| Jul 14 | $3.65 | $3.93 | $4.24 | -0.21% |
| Jul 15 | $3.60 | $3.93 | $4.28 | -0.28% |
| Jul 16 | $3.57 | $3.93 | $4.32 | -0.35% |
| Jul 17 | $3.53 | $3.92 | $4.36 | -0.42% |
| Jul 18 | $3.50 | $3.92 | $4.39 | -0.49% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.50 | $3.92 | $4.39 | -0.49% |
| Week 2 | $3.32 | $3.90 | $4.59 | -0.97% |
| Week 3 | $3.19 | $3.88 | $4.73 | -1.45% |
| Week 4 | $3.08 | $3.86 | $4.85 | -1.93% |
| Week 5 | $2.98 | $3.85 | $4.96 | -2.40% |
| Week 6 | $2.89 | $3.83 | $5.06 | -2.88% |
| Week 7 | $2.82 | $3.81 | $5.15 | -3.35% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BriaCell Therapeutics Corp. is a healthcare company described as a pre-clinical stage immuno-oncology firm that engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers.
The company is headquartered in West Vancouver, Canada.
BriaCell Therapeutics Corp. (BCTX) is a healthcare company with a current price of $3.94 and a market cap of $34.28M, ranking 4691. These figures place the stock within a broader market context, reflecting a small-cap healthcare profile.
A major floor 40.6% below — a decisive break under it would weaken the trend.
The nearest floor, 30.5% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 20.3% above — clearing it would confirm fresh momentum.
Key BCTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BCTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.65 | Buy | $3.67 | Buy |
| MA 10 | $3.44 | Buy | $3.50 | Buy |
| MA 20 | $3.16 | Buy | $3.36 | Buy |
| MA 50 | $3.46 | Buy | $3.50 | Buy |
| MA 100 | $3.79 | Buy | $4.29 | Sell |
| MA 200 | $6.38 | Sell | $7.01 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 67.32 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 175.43 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.12 | Buy |
| ROC (12) | 31.77 | Buy |
| Bollinger %B (20,2) | 1.06 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.13 | Sell |
| Awesome (5,34) | 0.42 | Buy |
| Ultimate (7,14,28) | 75.02 | Sell |
| Momentum (10) | 0.97 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 3.82 | Buy |
| ADX (14) | 19.48 | Neutral |
| ATR (14) | 0.13 | Info |
The current technical picture is labeled BULLISH, with RSI14 at 70. The 50-day moving average sits at $3.46 and the 200-day moving average at $6.38. Immediate support is at $2.74, while resistance is at $3.94. The 30-day price range spans $2.97 to $5.24, indicating recent volatility within a tight band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.74 | $3.94 | $5.06 | 0% | Neutral | |
| $2.90 | $3.85 | $5.50 | -2% | Neutral | |
| $2.73 | $3.80 | $5.72 | -4% | Neutral | |
| $2.57 | $3.71 | $5.83 | -6% | Neutral | |
| $3.60 | $5.39 | $8.76 | +37% | Bullish | |
| $3.78 | $5.86 | $9.81 | +49% | Bullish | |
| $3.24 | $5.18 | $8.90 | +31% | Bullish | |
| $3.49 | $5.75 | $10.12 | +46% | Bullish | |
| $3.19 | $5.40 | $9.72 | +37% | Bullish | |
| $2.99 | $5.21 | $9.57 | +32% | Bullish | |
| $3.66 | $7.25 | $14.47 | +84% | Bullish | |
| $7.42 | $16.48 | $37.04 | +318% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.74 | $3.94 | $4.68 | +0.00% |
| August 2026 | $3.03 | $3.64 | $4.52 | -7.68% |
| September 2026 | $3.05 | $3.70 | $4.67 | +1.67% |
| October 2026 | $3.20 | $3.92 | $5.02 | +5.97% |
| November 2026 | $3.16 | $3.90 | $5.06 | -0.47% |
| December 2026 | $3.10 | $3.86 | $5.06 | -1.04% |
Click any year to see its month-by-month BCTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
BriaCell Therapeutics Corp.'s 2026 outlook centres on $3.94, within a $2.74 to $5.06 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, BCTX could reach as high as $5.50, with a base case around $3.85 and support toward $2.90 — roughly -2% from $3.94. A consolidation phase looks the most probable path here.
Expect BCTX to range from $2.73 to $5.72 through 2028. The $3.80 average target implies a -4% move from current prices. That is -1% versus the projected 2027 average. Price action looks broadly range-bound.
The BCTX price prediction for 2029 points to an average of $3.71 (low $2.57, high $5.83) — a potential decline of -6% on today's $3.94. A consolidation phase looks the most probable path here.
In 2030, BCTX is projected to trade between $3.60 and $8.76, averaging $5.39 — a potential gain of +37% from today's $3.94. That is up +45% on the projected 2029 average. Momentum favours further upside here.
BriaCell Therapeutics Corp.'s 2031 outlook centres on $5.86, within a $3.78 to $9.81 range. That is up +9% on the projected 2030 average. That marks a +49% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, BCTX could reach as high as $8.90, with a base case around $5.18 and support toward $3.24 — roughly +31% from $3.94. Momentum favours further upside here.
Expect BCTX to range from $3.49 to $10.12 through 2033. The $5.75 average target implies a +46% move from current prices. That is up +11% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The BCTX price prediction for 2034 points to an average of $5.40 (low $3.19, high $9.72) — a potential gain of +37% on today's $3.94. Momentum favours further upside here.
In 2035, BCTX is projected to trade between $2.99 and $9.57, averaging $5.21 — a potential gain of +32% from today's $3.94. That is -3% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
BriaCell Therapeutics Corp.'s 2040 outlook centres on $7.25, within a $3.66 to $14.47 range. That is up +39% on the projected 2035 average. That marks a +84% change versus current levels. Momentum favours further upside here.
By 2050, BCTX could reach as high as $37.04, with a base case around $16.48 and support toward $7.42 — roughly +318% from $3.94. Buyers look set to stay in control over this stretch.
Investing $1,000 in BCTX today (≈ 253.807107 BCTX) could be worth
$4,183.43
+$3,183.43 (+318%) by 2050 · US Dollar
Based on the average projected BCTX price of $16.48 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BCTXwould be worth at today's price.
$1,000 invested in BCTX on Jul 10, 2025 (≈ 48.309177 BCTX) would be worth
$190.34
-$809.66 (-81.0%) today · 0.19× · US Dollar
Based on a BCTX entry price of $20.7 vs. today's $3.94.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.26 | $1,208.59 | +20.9% |
| 1 month ago | $2.88 | $1,368.06 | +36.8% |
| 3 months ago | $4.28 | $920.56 | -7.9% |
| 6 months ago | $7.64 | $515.71 | -48.4% |
| 1 year ago | $20.7 | $190.34 | -81.0% |
| All time (5.0y) ago | $58.2 | $67.7 | -93.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BCTX forecast.
Our base-case forecast reaches $7.90 around 2050.
Implied market cap at $7.90: $68.73M
Forecasts show year-by-year price expectations with multi-year bullish momentum starting in 2030. For 2026 the min, avg and max are $2.74, $3.94 and $5.06 respectively, with ROI 0 and sentiment NEUTRAL. In 2030 the avg is $5.39 with a min of $3.60 and a max of $8.76, and ROI 36.9 with sentiment BULLISH.
The outlook strengthens further in 2040 (avg $7.25, min $3.66, max $14.47; ROI 84; sentiment BULLISH) and 2050 (avg $16.48, min $7.42, max $37.04; ROI 318.3; sentiment BULLISH). Earlier years (2027–2029) show neutral to negative near-term returns, while 2031–2034 and beyond continue to trend bullish with higher potential upside, highlighting long-term growth potential amid near-term volatility.
Tap a question to reveal the answer.
Avg $5.39, min $3.60, max $8.76; ROI 36.9; sentiment BULLISH.
Near term shows neutral sentiment with ROI 0 (2026) and negative ROI in 2027 (-2.2), 2028 (-3.6), and 2029 (-5.7). From 2030 onward, the outlook is bullish with higher average prices and positive ROIs (e.g., 2030 ROI 36.9; 2031 ROI 48.7; 2032 ROI 31.4; 2033 ROI 45.9; 2034 ROI 37; 2035 ROI 32.3; 2040 ROI 84; 2050 ROI 318.3).
Yes. The 2033 forecast shows a max of $10.12, with a 2033 avg of $5.75 and min of $3.49; ROI 45.9; sentiment BULLISH.
Current price $3.94; market cap $34.28M.
Min $2.74, avg $3.94, max $5.06; ROI 0; sentiment NEUTRAL.
BriaCell Therapeutics Corp. Community Discussion
0Share your BriaCell Therapeutics Corp. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.